Fredun Pharmaceuticals Acquires 26% Stake in Goodman Vetcare

Fredun Pharmaceuticals has acquired a 26% stake in Mumbai-based Goodman Vetcare Private Limited. The deal values the veterinary retail entity at approximately Rs 300 crore.

Reader Takeaway: FPL gains direct retail access to the high-growth pet health niche, though execution risk remains for Goodman’s expansion.

What just happened

Fredun Pharmaceuticals (FPL) has formalised its entry into India’s organized veterinary retail and pet-care market through this equity investment. The company will now hold a 26% stake in Goodman Vetcare, a player currently focused on Mumbai and Navi Mumbai operations.

Why this matters

This partnership serves as a vertical integration strategy for FPL. While FPL focuses on manufacturing and pharmaceutical technology, the association with Goodman provides a direct-to-consumer platform. Goodman Vetcare aims to scale its revenue significantly, targeting Rs 40 crore by FY27 and Rs 100 crore by FY31, supported by a planned expansion of at least eight new stores.

FPL Financial Context (FY26)

For the financial year 2026, Fredun Pharmaceuticals reported total revenue of Rs 639.12 crore, with an EBITDA of Rs 94.79 crore and a Profit After Tax (PAT) of Rs 33.21 crore. These figures provide the financial foundation from which FPL is financing its strategic expansion.

Risks to watch

Investors should monitor the execution of Goodman Vetcare’s infrastructure plans, specifically the commissioning of new warehouses and the timeline for store rollouts. As FPL acts as a minority shareholder, the effectiveness of the operational synergy and the ability to maintain profitability during rapid scaling will be the primary factors determining long-term value creation.

What to track next

The progression of Goodman Vetcare's store openings and the impact of the shared technology and inventory management systems on FPL’s consolidated margins in the coming quarters.